How to Prescribe Medical Cannabis Australia: 2026 Practitioner Guide

Last Updated: April 2026

If you're asking how to prescribe medical cannabis Australia in 2026, the answer depends on your patient's condition, your prescribing experience, and whether you're using registered or unapproved products. Australian practitioners can prescribe medicinal cannabis through three primary pathways: the Special Access Scheme (SAS) Part B for individual patients, the Authorised Prescriber Scheme (APS) for recurring prescriptions, or ARTG-registered products for specific approved indications.

As of 2026, the TGA's single online application system processes SAS-B requests in 5-10 business days (standard) or 1-2 days (urgent), with approval rates averaging 87% for first-time applications. However, state-based Schedule 8 permits and SafeScript checks remain mandatory across all jurisdictions before dispensing.

The 2026 Prescribing Workflow: From Patient Assessment to Script Issuance

Prescribing medicinal cannabis in 2026 follows a rigorous clinical pathway that exceeds standard pharmaceutical prescribing requirements. Here is the complete workflow:

1. Patient Assessment and Eligibility Screening

Before considering medicinal cannabis, practitioners must document:

Failed conventional therapies: Evidence that at least two standard treatments have been ineffective or intolerable
Diagnosis validation: Clear documentation of the condition (chronic pain, epilepsy, multiple sclerosis, chemotherapy-induced nausea, or off-label use with clinical justification)
Drug-dependence screening: Mandatory assessment of substance use history using the Alcohol Use Disorders Identification Test (AUDIT) or equivalent
Cognitive capacity assessment: Particularly for elderly patients or those with psychiatric comorbidities

2026 Update: The Royal Australian College of General Practitioners (RACGP) updated its prescribing guidelines in March 2026, requiring specific documentation of "therapeutic failure" before medicinal cannabis consideration for chronic pain conditions.

2. Documentation Requirements and Record-Keeping

Under 2026 regulations, your medical records must include:

Pre-prescription checklist: Completed assessment of clinical need, previous treatments, and risk factors
Informed consent: Documented discussion of risks including psychotropic effects, cognitive impairment, and potential for dependence
Product specification: Exact cannabinoid composition (THC:CBD ratios), delivery method (oral, inhaled, topical), and dosing schedule
Monitoring plan: Scheduled follow-up intervals (minimum 4-weekly for first 3 months, then 12-weekly)

3. The Prescription Process Step-by-Step

Once assessment is complete:

Check SafeScript: Mandatory in all states by 2026, this real-time monitoring system flags potential drug interactions and polypharmacy risks
Apply for TGA approval: Via the TGA's single online application (SAS-B or APS)
Obtain state permits: Schedule 8 permits required in NSW, VIC, QLD, and SA for Schedule 8 products (THC >2%)
Issue prescription: Maximum 3-month supply for Schedule 8 products
Dispensing verification: Patient must present ID and prescription at authorised pharmacy

Understanding Your Prescribing Pathways: SAS, SAS-B, Authorised Prescriber, and ARTG Routes

Choosing the correct pathway is critical for efficient prescribing in 2026:

Special Access Scheme (SAS) Part B

Best for: Individual patient prescriptions, one-off or short-term use, or when testing specific products.

2026 Processing Times:

Standard applications: 5-10 business days
Urgent applications (life-threatening or severe suffering): 1-2 business days
Repeat applications: 2-3 business days (if same patient/product)

Limitations: Cannot prescribe more than 3 months at a time. Requires separate application for each patient.

Authorised Prescriber Scheme (APS)

Best for: Practitioners treating multiple patients with similar conditions, or those establishing a medicinal cannabis clinic.

2026 Requirements:

Minimum 2 years post-qualification experience
Documented training in medicinal cannabis prescribing (RACGP or equivalent)
Scope of practice limited to specific products and conditions

Advantage: Once approved, no individual patient applications needed. Prescriptions valid for up to 12 months.

ARTG-Registered Products

Current 2026 Status: Only two fully ARTG-listed medicinal cannabis products remain available in Australia: Epidyolex (cannabidiol) for Dravet syndrome and Lennox-Gastaut syndrome, and Nabiximols (Sativex) for spasticity in multiple sclerosis.

Advantages: No TGA approval required, PBS subsidised for specific indications, standard prescription process.

Limitation: Extremely limited therapeutic scope.

Pathway Comparison Table (2026)

Feature	SAS-B	Authorised Prescriber	ARTG Product
Approval Time	5-10 days	4-6 weeks (initial)	Immediate
Cost to Patient	High ($150-400/month)	High ($150-400/month)	Low (PBS co-payment)
Prescription Validity	3 months max	12 months	12 months
State Permits Required	Yes (S8 products)	Yes (S8 products)	No (S4)

State-by-State Regulatory Variations and Approval Requirements (2026 Update)

While Commonwealth (TGA) approval is mandatory, state-based requirements create significant variation in prescribing practice:

Victoria

Key 2026 Requirements:

Victorian Schedule 8 treatment permit required for patients with drug-dependence history
SafeScript mandatory check before prescribing and dispensing
No permit required for non-drug dependent patients (2026 reform)

New South Wales

NSW Poisons and Therapeutic Goods Advisory Committee (PTGAC) approval required for Schedule 8 products
Maximum initial supply: 28 days for Schedule 8 products
Telehealth prescribing allowed with face-to-face assessment within 12 months

Queensland

Medicines and Poisons Advisory Committee (MPAC) approval required
24-hour SafeScript check mandatory
Specialist referral required for first-time Schedule 8 prescriptions (2026 requirement)

Western Australia

WA Department of Health approval via Medicines and Poisons Advisory Committee
30-day maximum initial supply
Pharmacy notification required within 48 hours of dispensing

South Australia

Therapeutic Goods Advisory Committee approval required
SafeScript integration completed in 2025, mandatory in 2026
Standard PBS co-payments apply for ARTG products only

Tasmania

Tasmanian Advisory Committee on Medicines and Poisons (TACMP) approval
Most restrictive state: maximum 14-day initial supply for Schedule 8 products
Face-to-face consultation required for first prescription

ACT

ACT Therapeutic Goods Advisory Committee approval
Telehealth prescribing permitted
Standard 3-month supply allowed

Northern Territory

NT Health Department approval
Longest processing time: 10-14 business days for state permits
Pharmacist notification mandatory

Cost Analysis, Patient Expenses, and Insurance Coverage in 2026

Understanding 2026 pricing structures is essential for patient counselling and treatment planning:

Product Pricing (2026)

Medicinal cannabis products in 2026 range from $150 to $400 per month depending on:

Product type: Oils ($150-250), dried flower ($200-350), capsules ($180-280)
THC content: Higher THC products cost 20-30% more
Brand: Domestic vs. imported products
Dispensing fees: $15-25 per script

PBS Coverage (2026)

As of April 2026, only two medicinal cannabis products have PBS listings:

Epidyolex (cannabidiol): PBS subsidised for Dravet syndrome and Lennox-Gastaut syndrome (co-payment: $31.60 general, $7.70 concessional)
Nabiximols (Sativex): PBS subsidised for moderate-severe spasticity in multiple sclerosis (co-payment: $31.60 general)

Important: All other medicinal cannabis products are fully out-of-pocket.

Private Health Insurance

2026 updates to private health insurance coverage:

Hospital cover: Some policies cover medicinal cannabis used during hospitalisation
Extras cover: Limited coverage for dispensing fees ($10-20 per script)
Chronic disease programs: Some funds subsidise up to 50% of ongoing medicinal cannabis costs for chronic pain or epilepsy

Cost Mitigation Strategies

To assist patients with 2026 out-of-pocket costs:

Pharmacy discount programs: Some chains offer 10-15% discounts for bulk purchase
Chronic disease management plans: Medicare rebates ($94.50 per item) can offset consultation costs
Pharmaceutical benefit scheme (PBS) alternatives: Consider ARTG-listed products where clinically appropriate

Clinical Protocols: Dosing, Titration, and Safety Monitoring

Condition-Specific Dosing Guidelines (2026)

Chronic Pain:

Starting dose: 2.5-5mg THC or 10-25mg CBD daily
Titration: Increase by 2.5mg THC or 10mg CBD every 3-7 days
Maximum: 20mg THC or 50mg CBD daily (unless specialist supervision)

Epilepsy:

Starting dose: 2.5mg/kg/day CBD
Target dose: 20-30mg/kg/day CBD
Titration: Weekly increases of 2.5mg/kg/day

Chemotherapy-Induced Nausea:

Starting dose: 2.5-5mg THC or 1:1 THC:CBD
Timing: 1 hour before chemotherapy
Duration: Short-term (3-7 days)

Drug Interaction Management

Critical 2026 Interactions:

Warfarin: Cannabidiol increases INR by 30-50% - monitor weekly initially
Antiepileptics: Clobazam levels increase 300-400% with CBD - reduce dose by 50%
Statins: CYP3A4 inhibition increases simvastatin and atorvastatin levels
SSRIs: Risk of serotonin syndrome with high-dose cannabis

Follow-Up Protocols

Standard Monitoring Schedule (2026):

Week 2: Safety check (side effects, adherence)
Week 4: Efficacy assessment, titration review
Month 3: Full review, blood work (if on interacting meds), continuation decision
Every 3 months: Ongoing monitoring, Schedule 8 permit renewal (if applicable)

Telehealth and Interstate Prescribing Considerations

2026 Telehealth Regulations:

Medicinal cannabis can be prescribed via telehealth in 2026, but with restrictions:

First consultation: Must be face-to-face or video (not phone-only) in most states
Interstate prescribing: Allowed if practitioner is registered in the patient's state
SafeScript limitations: Interstate SafeScript sharing now complete (2025 reform), but processing takes 24 hours

Interstate Prescribing Rules:

Practitioners can prescribe across state borders in 2026, but must comply with the patient's state regulations regarding Schedule 8 permits and dispensing requirements.

Frequently Asked Questions

How long does it take to get TGA approval for medicinal cannabis in 2026?

Standard SAS-B applications take 5-10 business days. Urgent applications (life-threatening conditions) take 1-2 business days. Authorised Prescriber Scheme applications take 4-6 weeks initially but allow ongoing prescribing without individual patient approvals.

Can I prescribe medicinal cannabis via telehealth in 2026?

Yes, but the first consultation must typically be face-to-face or video-based. Interstate prescribing is permitted if you're registered in the patient's state. Check SafeScript and state-specific Schedule 8 permit requirements.

What are the costs for patients in 2026?

Most medicinal cannabis products cost $150-400 per month out-of-pocket. Only Epidyolex and Nabiximols have PBS subsidies ($31.60 co-payment). Private health insurance rarely covers the medication itself, though some funds cover dispensing fees.

Do I need a Schedule 8 permit in 2026?

Yes, for products containing THC >2%. Requirements vary by state: Victoria requires permits for drug-dependent patients only (2026 reform); NSW, QLD, and SA require permits for all Schedule 8 prescriptions; WA, TAS, ACT, and NT have specific approval processes.

How often should I follow up with patients?

Initial follow-up at 2 weeks (safety), 4 weeks (efficacy/titration), and 3 months (full review). Ongoing monitoring every 3 months. Schedule 8 permits require renewal every 12 months in most states.

What conditions are approved for medicinal cannabis in 2026?

SAS-B allows prescribing for any condition with clinical justification. PBS-listed indications include Dravet syndrome, Lennox-Gastaut syndrome, and MS spasticity. Common SAS-B uses include chronic pain, chemotherapy-induced nausea, epilepsy, and multiple sclerosis.

Can I prescribe dried flower products?

Yes, but dried flower is Schedule 8 and requires additional documentation. Average cost is $200-350/month. Patients must use vapourisers (not combustion) due to state smoking regulations.